Table 1. Characteristics of the study population - AGES-Reykjavik Study, Health Professionals Follow-up Study (HPFS) and Physicians’ Health Study (PHS).
| AGES-Reykjavik | HPFS | PHS | |||||
|---|---|---|---|---|---|---|---|
|
| |||||||
| Overall (n = 138) |
Fatal (n = 24) |
Controls (n = 1,214) |
Fatal (n = 40) |
Controls (n = 204) |
Fatal (n = 105) |
Controls (n=255) |
|
|
| |||||||
| Age at blood draw, y; mean (SD) | 76.7 (5.6) | 64.5 (7.7) | 59.0 (8.3) | ||||
| Prevalent cases | 79.0 (5.5) | 80.7 (6.4) | ---- | ---- | |||
| Incident cases | 75.5 (5.1) | 78.9 (5.1) | 67.9 (7.5) | 61.6 (7.9) | |||
|
| |||||||
| Cases Only | |||||||
|
| |||||||
| AGES-Reykjavik | HPFS | PHS | |||||
|
| |||||||
| Overall (n = 138) |
Fatal (n = 24) |
Fatal (n = 40) |
Fatal (n = 105) |
||||
|
| |||||||
| Time from blood draw to diagnosis, y; mean (SD)a |
2.6 (1.8) | 1.7 (1.8) | 3.9 (2.4) | 8.7 (5.1) | |||
|
| |||||||
| Time from diagnosis to blood draw, y; mean (SD)b |
6.1 (4.6) | 5.4 (4.1) | — | — | |||
|
| |||||||
| Time from diagnosis to fatal prostate cancer, y; mean (SD) |
---- | 6.8 (4.7) | 5.2 (2.8) | 6.2 (4.7) | |||
|
| |||||||
| Stage at diagnosisc | ---- | ---- | |||||
| T1/T2/T3a | 17 (43%) | 39 (38%) | |||||
| T3b | 6 (15%) | 17 (16%) | |||||
| T4 or N1 or M1 | 16 (40%) | 48 (46%) | |||||
|
| |||||||
| Gleason score at diagnosisc | ---- | ---- | |||||
| 2-6 | 0 | 14 (13%) | |||||
| 7 | 12 (30%) | 20 (19%) | |||||
| 8-10 | 24 (60%) | 58 (55%) | |||||
| Missing | 4 (10%) | 13 (13%) | |||||
Overall = total prostate cancer; fatal = death from prostate cancer
a
Incident cases (n=86)
b
Prevalent cases (n=52)
c
Stage and Gleason information was not available for the cases in AGES-Reykjavik